Benfotiamine
From Wikipedia, the free encyclopedia
 |
|
|
Benfotiamine
|
|
| Systematic (IUPAC) name | |
| S-[(Z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl- formylamino]-5-phosphonooxypent-2-en-3-yl] benzenecarbothioate |
|
| Identifiers | |
| CAS number | |
| ATC code | A11 |
| PubChem | |
| Chemical data | |
| Formula | C19H23N4O6PS |
| Mol. mass | 466.449 g/mol |
| Synonyms | S-benzoylthiamine-O-monophosphate |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Benfotiamine (rINN, or S-benzoylthiamine O-monophoshate) is a synthetic S-acyl derivative of thiamine (vitamine B1). After absorption, benfotiamine can be dephosphorylated by cells bearing an ecto-alkaline phosphatase to the lipid-soluble S-benzoylthiamine [1] [2]. The latter is able to cross cell membranes and enter the cells where it is transformed to thiamine. Benfotiamine should not be confused with allithiamine, a naturally occuring thiamine disulfide derivative [3].
[edit] Uses
The primary use of this antioxidant is as an "anti-AGE" supplement. [4] In a trial, benfotiamine lowered AGE by 40%.[5] However, in Germany doctors have been known to combine benfotiamine with pyridoxine hydrochloride and use it to treat patients with nerve damage and nerve pain such as sciatica.
Benfotiamine has shown to be an effective intervention for the treatment of diabetic retinopathy, neuropathy, and nephropathy, possibly because Benfotiamine is a transketolase activator that directs advanced glycation and lipoxidation end products (AGE's, ALE's) substrates to the pentose phosphate pathway, thus reducing tissue AGEs.[6][7][8][9]
[edit] References
- ^ Yamazaki M (1968), Studies on the absorption of S-benzoylthiamine O-monophosphate : (I) Metabolism in tissue homogenates. Vitamins 38 (1) 12–20.
- ^ M.L. Volvert, S. Seyen, M. Piette, B. Evrard, M. Gangolf, J.C. Plumier and L. Bettendorff (2008) Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacology 8: 10. http://www.biomedcentral.com/1471-2210/8/10
- ^ M.L. Volvert, S. Seyen, M. Piette, B. Evrard, M. Gangolf, J.C. Plumier and L. Bettendorff (2008) Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacology 8: 10. http://dx.doi.org/10.1186/1471-2210-8-10
- ^ Reducing Glycation Reactions for Better Health and Longer Life
- ^ J Lin, A Alt, J Liersch, RG Bretzel, M Brownlee (2000 May). "Benfotiamine Inhibits Intracellular Formation of Advanced Glycation End Products in vivo". Diabetes 49 (Suppl1) (A143).
- ^ Stirban A, Negrean M, Stratmann B, et al (2007). "Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method". Diabetes Care 30 (10): 2514–6. doi:. PMID 17630265.
- ^ Stracke H, Hammes HP, Werkmann D, et al (2001). "Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats". Exp. Clin. Endocrinol. Diabetes 109 (6): 330–6. doi:. PMID 11571671.
- ^ Stirban A, Negrean M, Stratmann B, et al (2006). "Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes". Diabetes Care 29 (9): 2064–71. doi:. PMID 16936154.
- ^ Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003). "Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine". Diabetes 52 (8): 2110–20. PMID 12882930.
[edit] External links
|
||||||||||||||
